Therefore, we integrated multiomics and immunotherapy data from melanoma and NSCLC samples, and found that FASN mutations could predict a preferable immunotherapeutic survival and response, which proposes a clinically potential indicator for choosing tumor patients to treat with immunotherapies. The gene discussed is FASN; the disease is neoplasm.